Letrozole
NDC Package 0054-0269-13

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Letrozole is a medication used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Marketed by West-ward Pharmaceuticals Corp., this product is identified by NDC 0054-0269 and is authorized under FDA application ANDA090838.

Identification & Billing

NDC Package Code
0054-0269-13
Package Description
30 TABLET in 1 BOTTLE
Product Code
0054-0269
11-Digit Billing Format
00054026913
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA

Clinical Specifications

Proprietary Name
Letrozole
Dosage Form
-
Usage Information
This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Regulatory & Marketing

Labeler Name
West-ward Pharmaceuticals Corp.
FDA Application #
ANDA090838
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-03-2011
End Marketing Date
01-30-2019
Listing Expiration
01-30-2019
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0054-0269-13 identifies a specific commercial package of 30 tablet in 1 bottle of Letrozole, labeled by West-ward Pharmaceuticals Corp.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by West-ward Pharmaceuticals Corp. on June 03, 2011. The current certification is valid through January 30, 2019.

What are the primary indications for this medication?

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

How is this West-ward Pharmaceuticals Corp. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00054026913. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0054-0269-13
11-Digit CMS (5-4-2)
00054-0269-13

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.